Trulieve's Great Unlock: NYSE Listing, Schedule III, and a Tripling Georgia Market

The first U.S. cannabis company on the Big Board resets its capital base even as Georgia's post-July 1 demand shock and a Texas license catalyst set up the next growth leg.

TRUL.CN · Earnings Call · 2026-08-07

The Structural Reset: NYSE, Schedule III, and a Restructured Balance Sheet

Trulieve entered Q2 2026 as a regional medical-cannabis operator and exited as the first U.S. cannabis company listed on the New York Stock Exchange. “We are thrilled to report second quarter results for the first time as a company listed on the New York Stock Exchange.” — Kimberly Rivers, Chief Executive Officer · 2026-08-07 The uplisting required a structural break: the company segregated its medical-only, DEA-registered business from the mixed-use Harvest operations, selling 10% of Harvest to an independent third party while retaining a 90% economic interest and an option to reconsolidate pending broader rescheduling. The accounting mechanics dominate the headline — the $406M net loss is essentially the $407M deconsolidation impact, with ex-items net income of $20M, or $0.11 per share. The regulatory tailwind is now real, not just aspirational. With state-licensed medical marijuana reclassified to Schedule III and Treasury confirming the punitive 280E tax no longer applies, the company's cash-flow base gets an immediate structural lift. Management remains confident in its uncertain tax position — a position that includes more than $102M in already-received IRS refunds — and the balance sheet reflects that conviction: $325M cash against $289M debt, $53M of Q2 operating cash flow, and a newly authorized $50M buyback.

Georgia Triples; Texas Waits on the Green Light

The growth narrative now hinges on two states, both reshaping the Medical Marijuana opportunity. Georgia's July 1 program expansion — lifting the THC cap, adding new qualifying conditions, and permitting vapes and flower — produced an immediate demand shock.

In the first 2 weeks of July, traffic at our dispensaries tripled. Due to high demand, we sold out of flower.
Kimberly Rivers, Chief Executive Officer · 2026-08-07

Patients have risen 24% since July 1 to above 45,000, triggering eligibility for an eighth dispensary. The independent pharmacy channel is forming in parallel — Trulieve now ships to nearly 20 pharmacies, with optionality ranging from straight wholesale to hybrid store-within-store arrangements and even pharmacy acquisitions. This is a notable evolution from the prior-quarter framing, when management described Georgia as a slower, programmatic ramp. Texas sits at the inflection point. The company has completed Phase 1 cultivation and production, notified regulators it is ready for inspections, and awaits conversion of its conditional license to final. “We will be moving very quickly as soon as we get the green light that our license has converted to final.” — Kimberly Rivers, Chief Executive Officer · 2026-08-07 In the prior quarter, the milestone was the provisional license itself; now the capital is built and the wait is purely regulatory. Management frames Texas as potentially the largest medical market in the U.S. — 157,000 patients today versus a Florida-style 4% population penetration that would imply roughly 1.3 million patients. A third, less state-specific catalyst is the federal crackdown on the intoxicating hemp market. Kim Rivers estimated Florida's hemp market at around $4B — roughly double the state's regulated medical market — and Texas's at $6B. Management's targeted conversion strategy quantifies what was previously a qualitative theme, and the company flagged in November that “we have seen a step-up in enforcement, I would say, across markets.” — Kimberly Rivers, Chief Executive Officer (CEO) · 2025-11-05

Follow the Cash: Sustained Margins Fund the Next Wave

The financial engine remains best-in-class: Q2 revenue of $271M (medical-only $222M, +4% sequentially), gross margin of 60% (63% medical-only), and adjusted EBITDA of $98M — a 36% margin. Patient growth in Florida, Georgia, and Pennsylvania has accelerated, with Florida adding roughly 1,000 patients per week in July versus about 326 per week in Q1, aided by a new ground-game initiative. The Q3 guide is flat versus Q2's medical-only $222M, as Georgia's rebound offsets typical Florida summer seasonality, with growth expected to accelerate into year-end. The investor base is shifting alongside the fundamentals. Since uplisting, management has run non-deal roadshows with long-only funds, and “there is work that is being done... Many of these folks have cannabis prohibitions that are holdovers in their policies that they're working through committees to get removed.” — Kimberly Rivers, Chief Executive Officer · 2026-08-07 Index inclusion is framed as a matter of "when, not if," given the U.S. domicile now checks the box. What makes this report genuinely differentiated is the confluence of three company-specific unlocks — Schedule III economics, NYSE listing, and two early-stage state programs — none of which appear in the global keyword tape, which remains dominated by AI/data-center and tariff themes. Trulieve's Q2 keyword momentum reflects its own story: Medical Marijuana at the top, with independent pharmacy and hemp market rising alongside. If Texas converts, the next 12 months could see this playbook compound from a roughly $2.1B market-cap base.